



Neurotech secures leading Austrian medical devices specialist as distribution partner

- Dengg Medizintechnik Gmbh to exclusively distribute Mente Autism in Austria
 - Austria's fastest growing neurotechnology distributor
 - First shipment of devices expected by June following test study

Perth, Australia & Malta – 2 March 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), developer of quality medical solutions in the neuroscience space, has secured Dengg Medizintechnik Gmbh as its Austrian marketing and distribution partner for Mente Autism.

Founded in 2010, and based in Innsbruck, Dengg Medizintechnik Gmbh is a distributor for medical devices and consumables in the fields of urology, neurology and gynaecology, including for Natus Medical Incorporated and Schwarzer Gmbh among others. The company continues to experience strong growth across the business including becoming the fastest-growing neurotechnology distributor in Austria.

In conjunction with the new distribution agreement, Dengg will oversee a test study of Mente Autism to be conducted at a local university hospital children's department. This is anticipated to commence during March and run for six to eight weeks.

While the specific terms of the distribution agreement with Dengg Medizintechnik Gmbh remain confidential, Neurotech expects to ship the first batch of devices immediately following the test study.

Wolfgang Storf, CEO of Neurotech International said: “This is a high quality new partner for Neurotech as we spread our rollout of Mente Autism into a new region, and is the culmination of concerted efforts to identify and secure the most appropriate partners for Neurotech in our key target markets. Dengg has an excellent track record and experience in this field and we are confident that they are the right choice for our company's products.”

“Austria is a perfect stepping-stone to target German-speaking markets and from there, we can expand throughout the DACH (Germany, Austria and Switzerland) region. Partnering with an established distributor is key to building relationships with medical professionals and entities working in this field and, in particular, with patients on the autism spectrum.”

Dengg Medizintechnik Gmbh co-general manager Helga Dengg said: “For the past few years we have focused a lot on diagnostic products in the neurotechnology field. There is huge potential in the provision of therapy products and Mente Autism fits the bill. Partnering with Neurotech is a great opportunity to grow together and to enhance our portfolio.”

“The results of the test study will present an outstanding opportunity, with the associated hospital planning to expand its services in the neurofeedback field. We expect to be in the pole position to collaborate and provide Mente Autism as an important therapy for their young patients.”

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420